Journal/
conference:
JAMA Psychiatry
Organisation/s:
National Institutes of Health, USA
Funder:
This manuscript was supported
by federal funds from the National Institute on Drug
Abuse (NIDA) and the National Institutes of Health
(NIH). The PATH Study is supported with federal
funds from the Center for Tobacco Products (CTP),
the US Food and Drug Administration (FDA), and
the Department of Health and Human Services,
through an interagency agreement between FDA
CTP and NIH NIDA, and through a collaboration
between NIDA and the National Cancer Institute,
the National Institute on Minority Health and
Health Disparities, the National Heart, Lung, and
Blood Institute, the National Institute on Alcohol
Abuse and Alcoholism, the National Institute of
Environmental Health Sciences, the Office of
Behavioral and Social Sciences Research, the Office
of Disease Prevention, the National Institute of
Diabetes and Digestive and Kidney Diseases, and
the National Library of Medicine. The PATH Study is
supported with federal funds from NIH NIDA and
FDA CTP, under contract toWestat (contract
numbers HHSN271201100027C and
HHSN271201600001C). Drs Blanco, Creamer,
Kimmel, and Compton were substantially involved
in providing scientific expertise and providing
scientific management for contract numbers
HHSN271201100027C and HHSN271201600001C.
Sign In
International
